NCT03658447View on ClinicalTrials.gov

PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 12, 2019

Primary Completion Date

December 22, 2022

Study Completion Date

December 22, 2022

Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
DRUG

Pembrolizumab

200mg Pembrolizumab given 3 weekly for upto 35 cycles

DRUG

177Lu-PSMA

6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.

Trial Locations (4)

2010

St Vincent's Hospital Sydney, Sydney

2050

Chris O'Brien Lifehouse, Sydney

3000

Peter MacCallum Cancer Centre, Melbourne

3128

Box Hill Hospital, Melbourne

All Listed Sponsors
lead

Peter MacCallum Cancer Centre, Australia

OTHER

NCT03658447 - PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) | Biotech Hunter | Biotech Hunter